Safety

Joseph L
Actual Nurtec ODT Patient

Well tolerated for acute and
preventive treatment

Most Common (≥2%) Adverse Events

Percentage of patients
that experienced nausea1-3

Acute (one 75 mg dose)

2%Nurtec ODT
n=682

0.4%Placebo
n=693

Preventive (75 mg dose every other day)

2.7%Nurtec ODT
n=370

0.8%Placebo
n=371

Percentage of patients
that experienced
abdominal pain/dyspepsia1,3

Preventive (one 75 mg dose every other day)

2.4%Nurtec ODT
n=370

0.8%Placebo
n=371

Well tolerated in
preventive study
2%discontinuation
due to AEs3

Nurtec ODT was not associated with any serious
treatment‑related AEs.3

Long‑term safety maintained through 52 weeks1

1798 patients were exposed to >111,000 doses of rimegepant4

Up to 18 doses of Nurtec ODT can be taken per month.1

A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).5

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. 4. Data on File. RIM113. Biohaven Pharmaceuticals Inc. 5. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long‑term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; April 17, 2020.